Abstract：【Objective】To investigate the effects of high flux hemodialysis on TLC, immunoglobulin level and QOL in the treatment of patients with chronic renal failure uremia . 【Methods】A total of 100 patients with chronic renal failure uremia from December 2012 to December 2015 in our hospital were collected and randomly divided into experiment group and control group with 50 cases in each group. Patients in the control group were treated by hemodialysis filtration treatment, three times a week; patients in the experiment group were treated by high flux hemodialysis therapy, three times a week, 28 d as a course of treatment. The TLC, immunoglobulin level and QOL of the two groups were compared before and after treatment . 【Results】 At the end of the treatment, the effective rate of the experiment group (96.0%,48/50) was higher than that of the control group (86.0%,43/50), the difference was statistical significance (P<0.05); Compared with before treatment, the serum creatinine level of the two groups were decreased , immunoglobulin IgA, IgM and IgG levels were increased, lung function TLC level increased , quality of life index (QOL) score increased (P<0.05), the difference was statistical significance . Compared with control group, the serum creatinine level of the experiment group was lower , immunoglobulin IgA, IgM and IgG levels were higher,TLC lung function level was higher, quality of life index (QOL) scored was higher (P<0.05), the difference was statistical significance ; Compared with the control group, the clinical complications rate of the experiment group was lower, the difference was statistical significance(P<0.05). 【Conclusion】Compared with hemodialysis, high flux hemodialysis treatment can better improve the patient's lung function, enhance immune function, improve the patient's QOL, which is worthy of clinical application.
任志龙;张璐;刘杰;苏可;杨定平. 高通量血液透析对慢性肾衰竭尿毒症患者肺总量、免疫球蛋白水平及生活质量的影响[J]. 医学临床研究, 2017, 34(1): 8-11.
REN Zhi-long, ZHANG Lu, LIU Jie,et al. Effects of High Flux Hemodialysis on TLC, Immunoglobulin Level and QOL in Treatment Chronic Renal Failure Uremia. JOURNAL OF CLINICAL RESEARCH, 2017, 34(1): 8-11.
[1] Vaziri ND, Wong J, Pahl M, et al. Chronic kidney disease alters intestinal microbial flora[J]. Kidney Int, 2013, 83(2): 308-315. [2] Popolo A, Autore G, Pinto A, et al. Oxidative stress in patients with cardiovascular disease and chronic renal failure[J]. Free Radic Res, 2013, 47(5): 346-356. [3] Carrero JJ, Stenvinkel P, Cuppari L, et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM)[J]. J Ren Nutr, 2013, 23(2): 77-90. [4] Yeung CK, Shen DD, Thummel KE, et al. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport[J]. Kidney Int, 2014, 85(3): 522-528. [5] Ruiz S, Pergola PE, Zager RA, et al. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease[J]. Kidney Int, 2013, 83(6): 1029-1041. [6] Maizel J, Six I, Dupont S, et al. Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure[J]. Kidney Int, 2013, 84(3): 491-500. [7] Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease[J]. Kidney Int, 2013, 83(6): 1010-1016. [8] Ikizler T A, Cano N J, Franch H, et al. Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism[J]. Kidney Int, 2013, 84(6): 1096-1107. [9] Moradi H, Sica DA, Kalantar-Zadeh K. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease[J]. Am J Nephrol, 2013, 38(2): 136-148. [10] Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome[J]. Am J Kidney Dis, 2013, 368(23): 2169-2181. [11] Vitetta L, Gobe G. Uremia and chronic kidney disease: The role of the gut microflora and therapies with pro‐and prebiotics[J]. Mol Nutr Food Res, 2013, 57(5): 824-832. [12] Vaziri ND, Yuan J, Khazaeli M, et al. Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption[J]. Am J Nephrol, 2013, 37(6): 518-525. [13] Neirynck N, Vanholder R, Schepers E, et al. An update on uremic toxins[J]. Int Urol Nephrol, 2013, 45(1): 139-150. [14] Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention[J]. Lancet, 2013, 382(9889): 339-352. [15] Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging[J]. Am J Kidney Dis, 2013, 62(2): 339-351. [16] Vaziri ND, Yuan J, Nazertehrani S, et al. Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction[J]. Am J Nephrol, 2013, 38(2): 99-103. [17] Alatriste PVM, Arronte RU, Espinosa COG, et al. Effect of probiotics on human blood urea levels in patients with chronic renal failure[J]. Nutr Hosp, 2014, 29(3): 582-590. [18] Phan O, Maillard M, Peregaux C, et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats[J]. J Pharmacol Exp Ther, 2013, 346(2): 281-289. [19] Bugnicourt JM, Godefroy O, Chillon J M, et al. Cognitive disorders and dementia in CKD: the neglected kidney-brain axis[J]. J Am Soc Nephrol, 2013, 24(3): 353-363. [20] Abed M, Artunc F, Alzoubi K, et al. Suicidal erythrocyte death in end-stage renal disease[J]. J Mol Med, 2014, 92(8): 871-879.
2017, Vol. 34 
